Deferasirox (Exjade, ICL670) efficiently removes labile plasma iron as compared to desferioxamine and deferiprone: A 24-hour monitoring study in thalassemia major patients

被引：0
|
作者：
Zanninelli, G.
Sorrentino, F.
Iazzoni, R.
Marzano, R.
Breuer, W.
Cabantchik, Z. I.
Cianciulli, P.
机构：
[1] Osped Sant Eugenio 1, Unita Day Hosp Talassemici, Rome, Italy
[2] Hebrew Univ Jerusalem, Dept Biol Chem, Jerusalem, Israel
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2007年 / 82卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：536 / 537
页数：2
相关论文
共 16 条
  • [1] Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670).
    Cohen, A
    Masera, G
    Zoumbos, N
    Uysal, Z
    Boulet, D
    Watman, N
    Loggetto, S
    Opitz, H
    Gathmann, I
    Alberti, D
    BLOOD, 2005, 106 (11) : 242A - 242A
  • [2] Plasma LPI in β-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670).
    Daar, S
    Taher, A
    Pathare, A
    Krahn, U
    Gathmann, I
    Nick, H
    Hadler, D
    BLOOD, 2005, 106 (11) : 758A - 758A
  • [3] Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS)
    List, Alan F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    BLOOD, 2007, 110 (11) : 440A - 440A
  • [4] Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 513 - 514
  • [5] Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients.
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    Capdeville, Renaud
    BLOOD, 2006, 108 (11) : 503A - 503A
  • [6] Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden
    Taber, Ali
    Al Jefri, Abdullah
    Elalfy, Mollsen Saleh
    Al Zir, Kusai
    Daar, Shahina
    Damanhouri, Ghazi
    Kriemler-Krahn, Ulrike
    Pfluger, Dietrich
    Hadler, Dominik
    El-Beshlawy, Aural
    BLOOD, 2007, 110 (11) : 817A - 817A
  • [7] Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)
    Gattermann, N.
    Schmid, M.
    Vassilieff, D.
    Rose, C.
    Porta, M. G. Dell
    Finelli, C.
    Taylor, K.
    Seymour, J. F.
    Lee, J. W.
    Jakobs, P.
    Domokos, G.
    Hadler, D.
    LEUKEMIA RESEARCH, 2007, 31 : S109 - S110
  • [8] A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
    Cappellini, MD
    Cohen, A
    Piga, A
    Bejaoui, M
    Perrone, S
    Agaoglu, L
    Aydinok, Y
    Kattamis, A
    Kilinc, Y
    Porter, J
    Capra, M
    Galanello, R
    Fattoum, S
    Drelichman, G
    Magnano, C
    Verissimo, M
    Athanassiou-Metaxa, M
    Giardina, P
    Kourakli-Symeonidis, A
    Janka-Schaub, G
    Coates, T
    Vermylen, C
    Olivieri, N
    Thuret, I
    Opitz, H
    Ressayre-Djaffer, C
    Marks, P
    Alberti, D
    BLOOD, 2006, 107 (09) : 3455 - 3462
  • [9] Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670)
    Piga, A
    Fischer, R
    Harmatz, P
    St Pierre, TG
    Longo, F
    Fung, E
    Engelhardt, R
    Perrotta, S
    Galanello, R
    Capra, M
    Vichinsky, E
    Janka-Schaub, G
    Masera, G
    Cianciulli, P
    Coates, T
    Janssen, G
    Jeng, M
    Lai, ME
    Salles, G
    Cole, P
    Alberti, D
    Rosenkranz, G
    Opitz, H
    BLOOD, 2005, 106 (11) : 755A - 755A
  • [10] IRON CHELATION THERAPY WITH DEFERASIROX (ICL670) REDUCES SERUM FERRITIN (SF) AND LABILE PLASMA IRON (LPI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    List, A. F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 91 - 92
12